Literature DB >> 34903587

Withaferin A in the Treatment of Liver Diseases: Progress and Pharmacokinetic Insights.

Yangliu Xia1, Mingrui Yan1, Ping Wang1, Keisuke Hamada1, Nana Yan1, Haiping Hao1, Frank J Gonzalez2, Tingting Yan1.   

Abstract

Withaferin A (WA) is a natural steroidal compound used in Ayurvedic medicine in India and elsewhere. Although WA was used as an anticancer reagent for decades, its role in the treatment of liver diseases has only recently been experimentally explored. Here, the effects of WA in the treatment of liver injury, systematic inflammation, and liver cancer are reviewed, and the toxicity and metabolism of WA as well as pharmacological potentials of other extracts from Withania somnifera (W. somnifera) discussed. The pharmacokinetic behaviors of WA are summarized and pharmacokinetic insights into current progress and future opportunities are highlighted. SIGNIFICANCE STATEMENT: This review outlines the current experimental progress of Withaferin A (WA) hepatoprotective activities and highlights gaps in the field. This work also discusses the pharmacokinetics of WA that can be used to guide future studies for the possible treatment of liver diseases with this compound. U.S. Government work not protected by U.S. copyright.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34903587      PMCID: PMC9132099          DOI: 10.1124/dmd.121.000455

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.579


  77 in total

1.  Effect of nuclear receptor downregulation on hepatic expression of cytochrome P450 and transporters in chronic hepatitis C in association with fibrosis development.

Authors:  Kazuhiko Hanada; Kenya Nakai; Hiromasa Tanaka; Fumitaka Suzuki; Hiromitsu Kumada; Yasuo Ohno; Shogo Ozawa; Hiroyasu Ogata
Journal:  Drug Metab Pharmacokinet       Date:  2011-12-13       Impact factor: 3.614

2.  Controlled-release systemic delivery - a new concept in cancer chemoprevention.

Authors:  Ramesh C Gupta; Shyam S Bansal; Farrukh Aqil; Jeyaprakash Jeyabalan; Pengxiao Cao; Hina Kausar; Gilandra K Russell; Radha Munagala; Srivani Ravoori; Manicka V Vadhanam
Journal:  Carcinogenesis       Date:  2012-06-13       Impact factor: 4.944

3.  In vitro assessment of CYP1A2 and 2C9 inhibition potential of Withania somnifera and Centella asiatica in human liver microsomes.

Authors:  Jay Savai; Alice Varghese; Nancy Pandita; Meena Chintamaneni
Journal:  Drug Metab Pers Ther       Date:  2015-06

4.  Glycyrrhizin Protects against Acetaminophen-Induced Acute Liver Injury via Alleviating Tumor Necrosis Factor α-Mediated Apoptosis.

Authors:  Tingting Yan; Hong Wang; Min Zhao; Tomoki Yagai; Yingying Chai; Kristopher W Krausz; Cen Xie; Xuefang Cheng; Jun Zhang; Yuan Che; Feiyan Li; Yuzheng Wu; Chad N Brocker; Frank J Gonzalez; Guangji Wang; Haiping Hao
Journal:  Drug Metab Dispos       Date:  2016-03-10       Impact factor: 3.922

5.  Role of CYP2E1 in the hepatotoxicity of acetaminophen.

Authors:  S S Lee; J T Buters; T Pineau; P Fernandez-Salguero; F J Gonzalez
Journal:  J Biol Chem       Date:  1996-05-17       Impact factor: 5.157

6.  Determination of withaferin A and withanolide A in mice plasma using high-performance liquid chromatography-tandem mass spectrometry: application to pharmacokinetics after oral administration of Withania somnifera aqueous extract.

Authors:  Dada Patil; Manish Gautam; Sanjay Mishra; Suresh Karupothula; Sunil Gairola; Suresh Jadhav; Shrikrishna Pawar; Bhushan Patwardhan
Journal:  J Pharm Biomed Anal       Date:  2013-03-26       Impact factor: 3.935

7.  Withaferin A sensitizes TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP.

Authors:  Tae-Jin Lee; Hee Jung Um; Do Sik Min; Jong-Wook Park; Kyeong Sook Choi; Taeg Kyu Kwon
Journal:  Free Radic Biol Med       Date:  2009-04-05       Impact factor: 7.376

8.  Hepatoprotective effect of withanolide-rich fraction in acetaminophen-intoxicated rat: decisive role of TNF-α, IL-1β, COX-II and iNOS.

Authors:  Santosh T Devkar; Amit D Kandhare; Anand A Zanwar; Suresh D Jagtap; Surendra S Katyare; Subhash L Bodhankar; Mahabaleshwar V Hegde
Journal:  Pharm Biol       Date:  2016-04-04       Impact factor: 3.503

9.  Withaferin A inhibits adipogenesis in 3T3-F442A cell line, improves insulin sensitivity and promotes weight loss in high fat diet-induced obese mice.

Authors:  Manizheh Khalilpourfarshbafi; Dharmani Devi Murugan; Munavvar Zubaid Abdul Sattar; Yamuna Sucedaram; Nor Azizan Abdullah
Journal:  PLoS One       Date:  2019-06-21       Impact factor: 3.240

10.  Safety and pharmacokinetics of Withaferin-A in advanced stage high grade osteosarcoma: A phase I trial.

Authors:  Nichelle Pires; Vikram Gota; Ashish Gulia; Lal Hingorani; Manish Agarwal; Ajay Puri
Journal:  J Ayurveda Integr Med       Date:  2019-03-21
View more
  1 in total

1.  Comparative Pharmacokinetics of Three Bioactive Diterpenoids of Rabdosia serra Extract in Normal and Con A-Induced Liver Injury Rats Using UPLC-MS/MS.

Authors:  Fangle Liu; Yun Zeng; Pengyu Dai; Kaiwen Huang; Kaihui Zhang; Tao Tao; Meiqi Wang; Chenchen Zhu; Chaozhan Lin
Journal:  Front Pharmacol       Date:  2022-07-12       Impact factor: 5.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.